Cordis to Present SELUTION SLR DEB Clinical Data at CRT 2026
By Azmed Devices Editorial Team
Cordis will present new 12-month clinical trial outcomes and procedural analyses for its SELUTION SLR Drug-Eluting Balloon at the upcoming CRT 2026 conference in Washington, D.C.
According to Cordis, the company is set to highlight significant insights from its SELUTION SLR Drug-Eluting Balloon (DEB) clinical program during the Cardiovascular Research Technologies (CRT) 2026 conference held in Washington, D.C. from March 7 to March 10. The scheduled presentations will feature 12-month results from the SELUTION4ISR and SELUTION DeNovo clinical trials, alongside new subset analyses that explore the role of operator experience in shaping treatment strategies with drug-eluting balloon technology.
According to Cordis, the upcoming presentations are intended to build upon previous findings where both the SELUTION4ISR and SELUTION DeNovo trials met their primary endpoints against current standards of care. Dr. George Adams, Chief Medical Officer at Cordis, noted that these sessions are designed to provide a deeper look into the 12-month outcomes of the technology while examining how real-world procedural experience influences clinical decision-making processes for medical professionals.
According to Cordis, the scientific program at CRT 2026 will include a series of late-breaking clinical trial data, oral presentations, and an evening symposium titled A New Chapter in Drug-Eluting Technology. These sessions will cover a variety of studies, such as the Love-DEB study and specialized sub-studies of the SELUTION DeNovo trial. Conference attendees are encouraged to visit the Cordis booth to engage with the company’s broader portfolio of coronary, peripheral, and closure technologies.
Source
This article summarizes an official Cordis announcement. Read the original at https://cordis.com/emea/news/cordis-to-present-selution-slr-deb-clinical-data-at-crt-2026. Product availability in Azerbaijan is subject to local registration; contact Azmed Devices for current status.
